01—Abstract
Summary
Summary of the 10-Q filed August 11, 2025. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group (UNH) reported solid top-line growth in its second quarter of 2025, with total revenues increasing by 13% year-over-year to $111.6 billiona.
This growth was driven by a strong performance in UnitedHealthcare, particularly Medicare Advantage and commercial offerings, which saw a 17% revenue increase and a 1.03 million increase in people served. Optum's revenue also grew by 6%, primarily fueled by Optum Rx. Despite revenue growth, earnings from operations saw a significant decline of 35% to $5.2 billionb, impacted by elevated medical cost trends, particularly within Medicare Advantage and the individual exchange offerings.
This was further compounded by the ongoing effects of the Inflation Reduction Act (IRA) on Medicare Part D, and increased unit costs and care activity. The company continues to manage these pressures through cost management initiatives and strategic pricing adjustments.
02—Key points
Key Highlights
- Total revenues grew 13% to $111.6 billion, driven by strong performances across UnitedHealthcare and Optum Rx.
- UnitedHealthcare revenue increased 17% to $86.1 billion, serving 1.03 million more people, primarily in Medicare Advantage and commercial segments.
- Optum revenue grew 6% to $67.2 billion, with Optum Rx showing significant growth.
- Earnings from operations decreased by 35% to $5.2 billion, largely due to elevated medical cost trends and the impact of the Inflation Reduction Act on Medicare Part D.
- Medical costs rose 20% year-over-year, impacting the medical care ratio (MCR) which increased to 89.4% from 85.1% in the prior year's quarter.
- The company repurchased approximately 6.1 million shares of common stock for $2.5 billion during the quarter.
- UnitedHealth Group's cash flow from operations was robust, reaching $12.6 billion for the six months ended June 30, 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, UnitedHealth Group Inc kept $0.03.
- Revenue$111.62B100.0%
- Cost of revenue−$13.02B11.7%
- Gross profit$98.60B88.3%
- Operating costs−$93.45B83.7%
- Operating income$5.15B4.6%
- Interest, other & tax−$1.74B1.6%
- Net income$3.41B3.1%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 11, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $111.62B$98.86B | +12.9% |
| Cost of Revenue | $13.02B$11.34B | +14.8% |
| Gross Profit | $98.60B$87.52B | +12.7% |
| SG&A Expenses | $13.78B$13.16B | +4.7% |
| Operating Expenses | $106.47B$90.98B | +17.0% |
| Operating Income | $5.15B$7.88B | −34.6% |
| Interest Expense | $1.03B$985.00M | +4.3% |
| Net Income | $3.41B$4.22B | −19.2% |
| EPS (Basic) | $3.76$4.58 | −17.9% |
| EPS (Diluted) | $3.74$4.54 | −17.6% |
| Shares Outstanding (Basic) | 907.00M921.00M | −1.5% |
| Shares Outstanding (Diluted) | 910.00M928.00M | −1.9% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the increase in medical costs?
The primary drivers for the increase in medical costs are the Inflation Reduction Act (IRA) impacting Medicare Part D plans, elevated overall medical cost trends (including increased unit costs and care activity), and growth in the number of individuals served in Medicare Advantage and those with higher acuity needs.
How did the company's segments perform in terms of revenue and earnings?
UnitedHealthcare saw a significant 17% revenue increase, but its earnings from operations decreased by 48% due to higher medical costs. Optum Health's revenue declined 7%, and its earnings from operations dropped 67%, also impacted by funding reductions and cost trends. Optum Insight's revenue grew 6% with a substantial 83% increase in earnings from operations, benefiting from reduced disruptions related to the Change Healthcare cyberattack. Optum Rx reported a 19% revenue increase and a 2% rise in earnings from operations, driven by higher script volumes and operational efficiencies.
What is the company's outlook regarding Medicare Advantage funding and risk adjustment?
The company notes ongoing pressure on Medicare Advantage funding, with industry base rates historically below forward medical cost trends. Significant revisions to the risk adjustment model are expected to result in reduced funding and potentially fewer benefits for beneficiaries, particularly those with complex health needs. The company is actively managing these pressures through cost management, network adjustments, benefit design changes, and careful selection of markets for offering plans.
Has the company made any significant share repurchases or dividend payments?
Yes, during the six months ended June 30, 2025, UnitedHealth Group repurchased approximately 12.1 million shares of common stock. The company also announced an increase in its quarterly cash dividend to an annual rate of $8.84 per share, up from $8.40 per share.
06—Continue